- Home
- CUE vs CODA Comparison
CUE vs CODA Comparison
Compare CUE & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | CODA |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 98.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CUE | CODA |
|---|---|---|
| Price | $0.24 | $9.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 695.9K | 48.1K |
| Earning Date | 11-12-2025 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.09 |
| EPS | N/A | ★ 0.30 |
| Revenue | $7,100,000.00 | ★ $24,347,217.00 |
| Revenue This Year | $36.58 | $30.82 |
| Revenue Next Year | $32.10 | $20.84 |
| P/E Ratio | ★ N/A | $31.80 |
| Revenue Growth | N/A | ★ 29.34 |
| 52 Week Low | $0.23 | $5.76 |
| 52 Week High | $1.75 | $10.54 |
Technical Indicators
Market Signals| Indicator | CUE | CODA |
|---|---|---|
| Relative Strength Index (RSI) | 13.49 | 60.27 |
| Support Level | $0.24 | $8.79 |
| Resistance Level | $0.51 | $9.69 |
| Average True Range (ATR) | 0.04 | 0.43 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 3.09 | 88.89 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.